Plooster Matthew R
Known title: DirectorCIK: 0001638364
Plooster Matthew R's purchase track record
Plooster Matthew R has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/9/2023 | ZVRA | $46K | +30.1% | +24.0% | +13.6% |
| 5/18/2022 | ZVRA | $25K | +12.6% | -7.8% | +0.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ZVRA | ▲ Buy | Open Market | 11,000 | $46K | 3/9/2023 | View on chart |
| ZVRA | ▲ Buy | Open Market | 915 | $5K | 5/18/2022 | View on chart |
| ZVRA | ▲ Buy | Open Market | 3,051 | $15K | 5/18/2022 | View on chart |
| ZVRA | ▲ Buy | Open Market | 339 | $2K | 5/18/2022 | View on chart |
| ZVRA | ▲ Buy | Open Market | 695 | $3K | 5/18/2022 | View on chart |
| ZVRA | ▲ Buy | Grant | 2,500 | $21K | 12/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price
Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price. Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.